anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a tablet resistant to coagulation even under a low pH condition, and dissolving rapidly in gastric juice to solubilize the active component, by compounding a sucrose fatty acid ester containing more than a specific amount of a monoester. CONSTITUTION:A sucrose fatty acid ester containing >=90% monoester and preferably containing a 8-22C fatty acid such as octanoic acid, lauric acid, stearic acid, oleic acid, etc., as the constituent fatty acid, is used as a component of a tablet at a ratio of >=50wt%. The dissolution of the active component in the gastric juice can be accelerated and the quick drug action can be attained by this method. Sucrose fatty acid ester is a nonionic surfactant having high safety, and is used widely in the fields of food, medicine, and cosmetic. Conven tional sucrose fatty acid ester forms a coagulum at a low pH and loses its dispersing power and solubilizing power. In contrast to the above, its monoester does not cause the coagulation even in a low pH region and has excellent solubilizing power to a water-insoluble component.
This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
The invention relates to an application of SIRT1 (silent mating type information regulation-1) in preparing upregulation globin gene expression and preparing a medicine for curing anemia. Particularly, the medicine is of purified protein type, the dosage form of the medicine can be any dosage form suitable for the application of the protein medicine. Particularly, the medicine can express the recombination nucleic acid construct of the SIRTI protein, and the expression carrier of the medicine can be any expression carrier suitable for gene therapy. Particularly, the globin gene is gamma globin or epsilon-globin, and the anemia is thalassemia or sicklanemia. Particularly, the thalassemia is beta-thalassemia. In the invention, a beneficial way for treating anemia caused by globin gene defects is provided.
BACKGROUND: Recent studies show a high prevalence of triangular fibrocartilage complex (TFCC) tears in asymptomatic wrists. While a TFCC tear may be identified when evaluating ulnar sided wrist pain, this could be incidental and not the true cause of pain. The purpose of this review was to (1) examine the frequency of which TFCC tears are diagnosed on MRI in asymptomatic versus symptomatic wrists and (2) determine whether rates of asymptomatic TFCC tears are higher in two important subgroups commonly at risk for this pathology: elderly patients and high-impact athletes.
METHODS: Articles of level IV or higher evidence were selected from PubMed, Ovid MEDLINE, and Cochrane Central Register of Controlled Trials Database to compare patient demographics, study parameters, and clinical outcomes.
RESULTS: Seven studies met inclusion criteria with a total of 501 wrists (205 symptomatic and 296 asymptomatic). All studies included asymptomatic patients with wrist MR imaging and included information on the structural integrity of the TFCC. Variability in outcome measures reported across studies prevented the conduction of a meta-analysis.
CONCLUSIONS: TFCC abnormalities are present in patients of all ages, symptomatology, and levels of involvement in high-impact sports. Although, there are differences in tear and abnormality prevalence when comparing these three factors, the difference was not significant. Given these findings, using MRI to assess ulnar-sided wrist pain should be fortified with clinical suspicion, physical exam, and physician judgment.
A composition is provided for chemoprevention of an oral cancer or precancerous condition, including an isolated berry preparation admixed with a bioadhesive carrier. The carrier may be a mucoadhesive gel. The berry preparation may be derived from one or more of strawberry, raspberry, red raspberry, and black raspberry. Methods for producing the compositions are provided also. There are also provided methods for chemoprevention of an oral cancer or precancerous condition, utilizing the compositions of the invention. Still further, methods for enhancing stability of an anthocyanin contained in the berry preparation of the invention are provided, along with methods for enhancing efficacy of the compositions.
Recent research in rodents suggests that oxidative stress, inflammation, and apoptosis in the testes caused by high-fat diets (HFD) are a cause of male infertility. To investigate the therapeutic efficacy of the combination of hydroxycitric acid and capsaicin (HCC) against male reproductive disorders, we developed an HFD-induced obese rat model. Rats received HFD supplementation for 21 weeks, which induced obesity. From week 16, HCC (100 mg/kg body weight) was administered to investigate its potential to treat testicular toxicity. According to the results of the current study, treatment of obese rats with HCC improved their sperm quality, increased the production of testosterone, follicle-stimulating hormone, and luteinizing hormone and significantly increased the activities of steroidogenic enzymes and corresponding mRNA levels. In addition, HCC decreased lipid peroxidation and nitric oxide levels in both spermatozoa and testes while increasing the expression of mRNA for the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase in the testes, which in turn reduced oxidative stress in the testes. Moreover, after HCC treatment, testicular tissues showed a remarkable decrease in mRNA levels responsible for inflammation (TNF-α, IL-6, NF-κB) and apoptosis (Bax and Bcl-2). Our results suggest that HCC may alleviate obesity-induced male reproductive dysfunction by attenuating oxidative stress, inflammation, and apoptosis in the testes of HFD-induced obese male rats.
An implant-supported denture placement and alignment system may include a denture apparatus. The denture apparatus may have a denture base and a denture base positioning system. The denture base may be connectable to implants. Moreover, the denture base positioning system may position the denture base in substantially the same position as a surgical guide used to place the implants. In this manner, the denture apparatus may be positioned so that it is mountable to the implants placed according to the surgical guide following their placement in a patient's mouth. In this manner, variations in the placement of the implants arising during the process of installing the implants may be compensated by transferring the actual implant positioning to the denture apparatus when it is positioned by the denture base positioning system.
Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
The complex of pentavalent rhenium 188 (Re-188) with dimercaptosuccinic acid is a compound with probable clinical application in the alleviation of pain due to bone metastases. The invention describes a simple method for the preparation in a single stage of the complex oxyrhenium-188 dimercaptosuccinic acid 188Re(V)-DMSA by the use of a kit. The invention also describes a kit of the radioactive drug which enables preparation of oxyrhenium-188 dimercaptosuccinic and 188Re(V)-DMSA in only one stage, the content of the kit being reconstituted with an injectable solution of hyperrhenic (Re-188) sodium, of volume > 1 ml. The kit contains all the ingredients needed for the purpose, in a stable in- vitro composition. The preparation method is particularly easy, effective and pharmaceutically appropriate, and the kit can be stored for a suitable time. The content of the kit is in the form of a lyophilised dry powder free from microbial contamination (sterile) and contains no pyretogens.
The present application relates to an aorta screening method, apparatus, computer device and storage medium. The method comprises the following steps: a raw image of the aorta is acquired. Analyzing and processing the original image of the aorta, and determining a plurality of segmentation masks of the aorta, a plurality of key points of the aorta and the continuous section diameter of the aorta, wherein the key points are contact points of branches of the aorta and an aorta trunk of the aorta. Determining a plurality of key sections according to the plurality of key points and the plurality of segmentation masks; the critical cross-section is used to characterize a physiological characteristic of the aorta. Determining an aortic risk level based on the plurality of critical sections and the continuous section diameter. The accuracy of aorta screening can be improved.
Aspirin has been shown to lower the number of EPCs in a time- and concentration-dependent manner. In vitro studies also show that aspirin may reduce the migratory and adhesive capacity of isolated EPCs, inhibit iNOS and tubule formation, which are pre-requisites for angiogenesis. This is relevant when patients are given a loading dose of 325mg at the time of diagnosis of acute myocardial infarction where higher numbers of EPCs have been associated with better outcomes. Furthermore, in the PLATO (Platelet Inhibition and Patient Outcomes) trial, high dose aspirin appeared to counteract the beneficial effect seen when ticagrelor or clopidogrel was used with low doses of aspirin in acute coronary syndromes (ACS).

As aspirin is currently standard of care in the management of ACS, it is difficult to conduct a study of the effect of aspirin versus placebo in that scenario. However, during alcohol septal ablation for hypertrophic obstructive cardiomyopathy, the indication for an antiplatelet agent is not well defined and varies between operators. When a small amount of myocardium is deliberately destroyed in this process, it serves as an ideal model to study the effect of aspirin on the biology of EPCs in vivo. This could provide an explanation to the different effects of high versus low dose aspirin when combined with a second antiplatelet agent in the management of ACS.
PROBLEM TO BE SOLVED: To further appropriately support transmission of medical information.SOLUTION: A guidance support system comprises a wearable terminal having imaging means for imaging a subject. The guidance support system comprises acquisition means, display means and processing means. The acquisition means acquires medical information corresponding to the subject. The display means displays the medical information acquired by the acquisition means. The processing means makes the image imaged by the imaging means associate with the medical information on the subject displayed by the display means. Thus, the guidance support system can support transmission of medical information.SELECTED DRAWING: Figure 1
Participants randomized to acupuncture will receive 12 weeks of acupuncture treatments delivered in a group setting, dosing similar to prior research. Acupuncture point selection and other treatment details will follow responsive manualization, a protocol developed for the largest clinical trial of group acupuncture to date. A licensed acupuncturist experienced with administering group acupuncture treatments will determine each participant's traditional Chinese medicine diagnosis and administer 8-10 acupuncture needles on distal points of participant's body (below the knees, from the elbows to the hands, and on the head). Duration of assessment, needle placement and retention will be 30-45 minutes. Details of acupuncture treatments (e.g., frequency and duration, traditional Chinese medicine diagnosis, number of needles and points used) will be documented in electronic health records.
PURPOSE OF REVIEW: Oral drug absorption after bariatric surgery is likely to be altered, but the impact of different bariatric surgery procedures on individual drugs is not uniform. The aim of this article is to describe factors influencing the bioavailability of orally administered drugs after bariatric surgery and to provide readers with practical recommendations for drug dosing. We also discuss the medications that may be harmful after bariatric surgery.
RECENT FINDINGS: The fundamental factors for enteral drug absorption are the production of gastric acid; the preserved length of the intestine, i.e., the size of the absorption surface and/or the preserved enterohepatic circulation; and the length of common loop where food and drugs are mixed with digestive enzymes and bile acids. Bypassing of metabolizing enzymes or efflux pumps and changes in intestinal motility can also play an important role. Significant changes of drug absorption early after the anatomic alteration may also be gradually ameliorated due to gradual intestinal adaptation. The most affected drugs are those with low or variable bioavailability and those undergoing enterohepatic circulation. Attention should also be paid to oral drug formulations, especially in the early postoperative period, when immediate-release and liquid formulations are preferred. The changes in oral bioavailability are especially clinically meaningful in patients treated with drugs possessing narrow therapeutic index (e.g., oral anticoagulants, levothyroxine, and anticonvulsants) or in acute conditions (e.g., anti-infectives); nevertheless, it may also influence the therapeutic value of chronic therapy (e.g., antidepressants. antihypertensives, antiplatelets, statins, PPIs, contraceptives, and analgesics); therapeutic effect of chronic therapy is further influenced by pharmacokinetic alterations resulting from weight loss. Therapeutic drug monitoring, periodical clinical evaluation, and adequate dose adjustments are necessary. Due to safety reasons, patients should avoid oral bisphosphonates, regular use of non-steroidal anti-inflammatory drugs, and, if possible, corticosteroids after bariatric surgery.
QDOLO may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics) [see Drug Interactions ( 7)] . Regularly evaluate patients for signs of hypotension after initiating or titrating the dosage of QDOLO. In patients with circulatory shock, QDOLO may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of QDOLO in patients with circulatory shock.
A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to \<60/min. The weaning process was initiated when the following parameters were achieved: PIP \<18 cmH2O, PEEP \<4 cmH2O, and FIO2 \<0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 \<0.3 and respiratory rate \<25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
OBJECTIVES: Monochorionic twins (MC) have higher risk of perinatal morbi-mortality compared to singletons and dichorionic twins (DC). Selective fetal growth restriction (sFGR) increases the chances of adverse outcome. Hepatic arterial buffer response (HABR) is an important mechanism for maintaining liver perfusion. We hypothesised that HABR is active in monochorionic diamniotic twins (MCDA) with sFGR where restricted fetus may have liver hypoperfusion. The objective of this study is to test whether the HAV-ratio is diminished in pregnancies affected by selective fetal growth restriction pointing to activation of HABR in the growth-restricted fetus.
METHODS: sFGR was defined according to a consensus definition. Hepatic artery (HA) peak systolic velocity (PSV) was measured and its correlation with fetal Dopplers and pregnancy characteristics were determined. A ratio using HA-PSV (HAV-ratio) was calculated and its association with sFGR was established. Further analysis of HA-PSV was performed comparing z-scores between normal and growth restricted fetuses.
RESULTS: We included 202 MCDA pregnancies, 160 (79 %) normal and 42 (21 %) with sFGR. HAV-ratio was significant different between groups. The mean HAV-ratio was 1.01 (±0.20) for normal twins and 0.77 (±0.25) for sFGR. Furthermore, HA-PSV z-scores was significant increased in in growth-restricted fetus (0.94±1.45), while in normal fetuses was -0.16 (±0.97).
CONCLUSIONS: Our findings demonstrate that, in pregnancies with sFGR, HAV-ratio is significantly lower than in normal MCDA pregnancies. The lower HAV-ratio is due to an increase in HA PSV in the growth restricted fetus. This observation indicates an activation of HABR in the small fetus.
Participants will be asked to reduce their free sugar intakes to less than 5% TEI. To aid with this, they will be asked to reduce their intakes of foods and drinks high in free sugars, and replace these with foods low in sugars, that remain high in taste, eg. nuts, foods and drinks flavoured with herbs and spices. The intervention will be provided to participants in written form, in an opaque sealed envelope.
Schools receiving a lower intensity nutrition education served as control. This group received 3 sessions of 1 hour with a total of 3 educational sessions over the 6 month period. The educational material was the same as the intervention group but the development of lessons was not as specific and deep as the intervention group.
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic malignancy for which there are currently no effective anti-metastatic therapies. Herein, we employed single-cell RNA sequencing and metabolomics analysis to demonstrate that metastatic cells highly express focal adhesion kinase (FAK), which promotes metastasis by remodeling choline kinase α (CHKα)-dependent choline metabolism. We designed a novel CHKα inhibitor, CHKI-03, and verified its efficacy in inhibiting metastasis in multiple preclinical models. Classical and newly synthesized small-molecule inhibitors have previously been used to assess the therapeutic potential of targeting mTOR and CHKα in various animal models. Mechanistically, FAK activated mTOR and its downstream HIF-1α, thereby elevating CHKα expression and promoting the proliferation, migration, and invasion of PDAC cells, as well as tumor growth and metastasis. Consistently, high expression levels of both FAK and CHKα are correlated with poor prognosis in patients with PDAC. Notably, CHK1-03 inhibited CHKα expression and also suppressed mTORC1 phosphorylation, disrupting the mTORC1-CHKα positive feedback loop. In addition, the combination of CHKI-03 and the mTORC1 inhibitor rapamycin synergistically inhibited tumor growth and metastasis in PDX models. The combination of CHKI-03 and rapamycin demonstrates considerable therapeutic efficacy in PDO models resistant to gemcitabine. Our findings reveal a pivotal mechanism underlying PDAC metastasis regulated by mTORC1-CHKα loop-dependent choline metabolism reprogramming, highlighting the therapeutic potential of this novel regimen for treating PDAC metastasis.
The invention relates to a window adjusting optimization method for a medical image. The method comprises the steps of firstly constructing a window adjusting optimization module, wherein the window adjusting optimization module is constructed by a window setting submodule and a converting submodule. And secondly, constructing a task requirement network, wherein the task requirement network is determined by specific task requirements. Then model training and verification are carried out. And finally, outputting window width and window level parameters according to task requirements, and outputting the window-adjusted and optimized image according to the requirements. According to the invention, the window width and window position parameters can be adaptively optimized by combining task requirements through the window adjusting optimization module, and the window adjusting optimized image can be generated.
ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with dismal prognosis. Genomic instability due to defects in cell-cycle regulation/mitosis or deficient DNA-damage repair is a major driver of PDAC progression with clinical relevance. Deregulation of licensing of DNA replication leads to DNA damage and genomic instability, predisposing cells to malignant transformation. While overexpression of DNA replication-licensing factors has been reported in several human cancer types, their role in PDAC remains largely unknown. We aimed here to examine the expression and prognostic significance of the DNA replication-licensing factors chromatin licensing and DNA replication factor 1 (CDT1), cell-division cycle 6 (CDC6), minichromosome maintenance complex component 7 (MCM7) and also of the ubiquitin ligase regulator of CDT1, cullin 4A (CUL4A), in PDAC.
MATERIALS AND METHODS: Expression levels of CUL4, CDT1, CDC6 and MCM7 were evaluated by immunohistochemistry in 76 formalin-fixed paraffin-embedded specimens of PDAC patients in relation to DNA-damage response marker H2AX, clinicopathological parameters and survival. We also conducted bioinformatics analysis of data from online available databases to corroborate our findings.
RESULTS: CUL4A and DNA replication-licensing factors were overexpressed in patients with PDAC and expression of CDT1 positively correlated with H2AX. Expression of CUL4A and CDT1 positively correlated with lymph node metastasis. Importantly, elevated CUL4A expression was associated with reduced overall survival and was an independent indicator of poor prognosis on multivariate analysis.
CONCLUSION: Our findings implicate CUL4A, CDT1, CDC6 and MCM7 in PDAC progression and identify CUL4A as an independent prognostic factor for this disease.
The invention which belongs to the physical physiatry relates to a simplest hemorrhoid treating method, and particularly relates to a simplest hemorrhoid control method. The method has the advantages of fastest effect and minimum cost. Hemorrhoid is a disease comprising that veins of an internal and external anus swell, vein blood is not easy to reflux, the anus is subjected to alligatoring, hyperemia and oedema, and circular or oval blocks and obvious haphalgesia appear. The disease is caused by bad eating habits, long squatting periods or overexertion cacation. There are a lot of hemorrhoid treating methods at home and abroad, and a satisfying effect is difficult to achieve in cure rate and cost. The invention aims to overcome deficiencies in current hemorrhoid treating and provide the most convenient and simple hemorrhoid treating method with low cost and high cure rate, and the method is a cold junction contraction therapy that only tap water is needed to wash the anus when the anus swell.